Showing 2701-2710 of 5771 results for "".
- The Vision Council Opens Registration for 2026 Executive Summithttps://modernod.com/news/the-vision-council-opens-registration-for-2026-executive-summit/2484153/The Vision Council announced that registration is open for the 2026 Executive Summit. The 3-day forum will be held January 26-28, 2026, at The Ritz-Carlton, Amelia Island, Florida.
- SightGlass Vision: New 18-Month Data Reinforce DOT Lens Effectivenesshttps://modernod.com/news/sightglass-vision-new-18-month-data-reinforce-dot-lens-effectiveness/2484152/New 18-month clinical data presented by SightGlass Vision at the American Academy of Optometry 2025 annual meeting show that more than half of children wearing DOT spectacle lenses experienced no clinically meaningful myopia progression—nearly 4 times th
- Virtual Field Launches DICOM 360 Sync Connectivity Hubhttps://modernod.com/news/virtual-field-launches-dicom-360-sync-connectivity-hub/2484151/Virtual Field announced the launch of DICOM 360 Sync, a connectivity hub that aims to redefine how practices connect diagnostics with medical records. DICOM 360 Sync is designed to deliver instant, autom
- Cirrus Therapeutics Raises $11 Million to Advance First-in-Class Ocular Gene Therapy Targeting Dry AMDhttps://modernod.com/news/cirrus-therapeutics-raises-11-million-to-advance-first-in-class-ocular-gene-therapy-targeting-dry-amd/2484149/Cirrus Therapeutics announced the close of an $11 million seed financing round to advance its gene and cell therapy pipeline. The company will use the funds to progress its lead program into IND-enabling studies.
- Oculis to Present Positive Phase 2 ACUITY Trial Results on Privosegtor for Acute Optic Neuritishttps://modernod.com/news/oculis-to-present-positive-phase-2-acuity-trial-results-on-privosegtor-for-acute-optic-neuritis/2484148/Oculis announced it will present phase 2 results for its investigational therapy Privosegtor (OCS-05) at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2025 Congress. The late-breaking abs
- Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Dealhttps://modernod.com/news/formycon-expands-european-footprint-for-aflibercept-biosimilar-fyb203-with-horus-pharma-deal/2484146/Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.